Navigation Links
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
Date:7/16/2009

y will have the right to promote the fixed-dose combination product to healthcare professionals in all countries except Japan and the access countries. Gilead will assume the lead role in manufacturing, registration and, subject to regulatory approval, commercialization of the fixed-dose combination of TMC278 and Truvada throughout the territory.

Tibotec and Gilead are committed to working together to make the fixed-dose combination of TMC278 and Truvada available in the developing world and will work towards a separate agreement for these countries.

About TMC278

TMC278 is an investigational non-nucleoside reverse transcriptase inhibitor, and the safety and efficacy of it, in combination with other antiretroviral agents, has not been established. Two major phase III trials for TMC278 are currently being conducted in the United States, Canada, Africa, Asia, Europe and South America.

About Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Tibotec Pharmaceuticals is a subsidiary of Johnson & Johnson.

Forward-Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Tibotec's expectations and projections. Risks and uncertainties include general in
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... that it has entered into a distribution agreement ... provide its dehydrated human amnion/chorion membrane ("dHACM") allograft ... on a private label basis. The ...
(Date:9/18/2014)... ANN ARBOR, Mich. , Sept. 18, 2014 /PRNewswire-USNewswire/ ... Medical Research will allow the University of Michigan to ... The Glenn Center for Aging Research ... growing evidence that drugs can slow the effects of ... to unlock mechanisms of aging that can help develop ...
(Date:9/18/2014)... announces the list of stocks featured in the Analyst ... the latest news and events impacting stocks and the ... Avanir Pharmaceuticals (Nasdaq: AVNR - Free Report ), ... Orexigen (Nasdaq: OREX - Free Report ), Medivation ... (Nasdaq: GILD - Free Report ). ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... ANGELES, Sept. 29, 2011 A west coast secret is ... All the way from Beverly Hills, California, a health and ... headlines ( www.endlessyouthandlife.com ).  A clinically tested dietary supplement is ... shown in less than 4 weeks of use.  Just a ...
... Awarepoint Corporation , the leading provider ... announced today that it received Frost & Sullivan,s ... Strategy Leadership Award .  The award recognizes ... and workflow automation solutions that significantly differentiates Awarepoint ...
Cached Medicine Technology:Beverly Hills Secret Now Helping People Across The Country 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 3
(Date:9/18/2014)... Relias Learning, the leader in SaaS-based training and ... announced it has been named to the Inc. 5000 list ... , In the three-year period from 2010 to 2013, Relias ... on the Inc. 5000 list to 1,025 from the company’s ... we serve continue to grow, and the need for quality ...
(Date:9/18/2014)... PlatinumCode, a leading manufacturer and ... for the healthcare industry, announced earlier this month ... of their profits of the sale of eligible ... the announcement, PlatinumCode has launched various marketing efforts ... and hospital labs with their popular “Pink Packs” ...
(Date:9/18/2014)... “Awesome” is the way Emily W. describes ... Today) Internship Program at ARDX ( http://www.ardx.net ). ... program as “Inspirational” and “Life-changing,” respectively. None of ... would be doing during their summer internship. Stacie ... other mindless tasks,” but, instead she was doing real, ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. ... number of post-traumatic stress disorder symptoms are almost three times ... study suggests. The findings don,t prove a direct ... food. And it,s also possible that certain women are prone ... Still, the research seems to add to existing evidence ...
(Date:9/18/2014)... Fit Body Boot Camp , an internationally ... the country and its popularity, as both a franchise and ... in 2014. , The company’s annual business conference, the ... Costa Mesa, CA on September 26 and 27, and is ... Bedros Keuilian, who is also considered the leading fitness marketing ...
Breaking Medicine News(10 mins):Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... MONDAY, Oct. 31 (HealthDay News) --,The longer they live in ... immigrants will develop health problems, a new study says. ... Nutrition Examination Survey and discovered a dramatic increase in obesity, ... in the United States for more than 20 years. ...
... developed a new way to assess a common cause ... Disease Activity Index. A study describing the index was ... Annual Scientific Meeting and Postgraduate Course in Washington. The ... severity. "Until now, physicians have not ...
... on nutrients carried to them by the blood stream. ... hallmark of cancer, and studies have shown that preventing ... To better understand the relationship between cancer and the ... of the complete network of blood vessels in organs. ...
... Tech-savvy teens with acne used their medicine more frequently ... a new study from Wake Forest Baptist Medical Center ... test whether a weekly Internet-based communication could improve teenagers, ... "Dermatologists have a number of effective topical agents for ...
... Surgeons at UK HealthCare recently became the first ever to ... transplantation. Wanda Craig, of Lexington, Ky., is the first patient ... of 68, she is also the oldest living human to ... known as an extracorporeal membrane oxygenation (ECMO). For more ...
... could help GPs to speed up the diagnosis and ... common forms of cancer, potentially saving thousands of lives ... and ClinRisk Ltd have shown that the algorithm is ... lung cancer at an earlier stage by ,red-flagging, potentially ...
Cached Medicine News:Health News:Life in U.S. Not Always a Plus for Immigrants' Health 2Health News:The power of the Internet: It helps improve teens' acne 2Health News:UK HealthCare surgeons are first to perform novel procedures prior to transplant 2Health News:UK HealthCare surgeons are first to perform novel procedures prior to transplant 3Health News:Computer-based tool to improve diagnosis and prognosis for cancer patients 2Health News:Computer-based tool to improve diagnosis and prognosis for cancer patients 3Health News:Computer-based tool to improve diagnosis and prognosis for cancer patients 4
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: